Patent · US Active

Universal donor cells

US11118195B2 · kind B2 · utility

6Cited by

29References

26Claims

0Family size

Assignee

CRISPR THERAPEUTICS AG · CH

Inventors

Alireza Rezania · Cambridge, US
Rebeca Ramos-Zayas · Cambridge, US

Key dates

Filing date	Sep 4, 2020
Grant date	Sep 14, 2021
Priority date	—
Expiry date	Sep 4, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/80
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.